Drug Approval | May 15, 2022
USFDA approves novel, dual-targeted treatment for type 2 diabetes
In clinical trials, treatment proved more effective than other therapies evaluated
In clinical trials, treatment proved more effective than other therapies evaluated
Q1 net sales increased by 12.2% to € 5,198 million compared with the year-earlier quarter
It is a new class of drug that treats uncontrolled LDLCholesterol, despite the use of a maximum tolerated dose of statins
East Syracuse site to serve as the LOTTE Center for North America Operations for LOTTE’s biologics contract development and manufacturing organization (CDMO) business
The pharma companies will bring quality products at competitive prices to consumers in Oman and help bring down the cost of healthcare
The licences will allow manufacturers from around the world to work with MPP and C-TAP to make these technologies accessible to people living in low- and middle-income countries
“We are committed to making India a global medical value hub by further strengthening our traditional medicine industry and boosting 'Heal in India' & 'Heal by India'
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
Deucravacitinib is currently under regulatory review in multiple regions, including the U.S., Europe and Japan, and would be the first selective allosteric tyrosine kinase 2 (TYK2) inhibitor approved for the treatment of any disease
Subscribe To Our Newsletter & Stay Updated
